RAMIPRIL capsule

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

RAMIPRIL (UNII: L35JN3I7SJ) (RAMIPRILAT - UNII:6N5U4QFC3G)

Verfügbar ab:

DirectRX

INN (Internationale Bezeichnung):

RAMIPRIL

Zusammensetzung:

RAMIPRIL 10 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

- 1.1 Hypertension Ramipril capsules are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. 1.3 Heart Failure Post-Myocardial Infarction Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsules to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see Clinical Studies ( 14.3)]. Ramipril capsules are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ram

Berechtigungsstatus:

Abbreviated New Drug Application

Fachinformation

RAMIPRIL- RAMIPRIL CAPSULE
DIRECTRX
----------
RAMIPRIL
BOXED WARNING SECTION
WARNING: FETAL TOXICITY•When pregnancy is detected, discontinue
ramipril as soon as
possible ( 5.6).•Drugs that act directly on the renin-angiotensin
system can cause injury and
death to the developing fetus ( 5.6).
INDICATIONS & USAGE SECTION
1.1 Hypertension
Ramipril capsules are indicated for the treatment of hypertension.
They may be used alone or in
combination with thiazide diuretics.
1.3 Heart Failure Post-Myocardial Infarction
Ramipril capsules are indicated in stable patients who have
demonstrated clinical signs of
congestive heart failure within the first few days after sustaining
acute myocardial infarction.
Administration of ramipril capsules to such patients has been shown to
decrease the risk of death
(principally cardiovascular death) and to decrease the risks of
failure-related hospitalization and
progression to severe/resistant heart failure [see Clinical Studies (
14.3)].
DOSAGE & ADMINISTRATION SECTION
2.1 Hypertension
The recommended initial dose for patients not receiving a diuretic is
2.5 mg once a day. Adjust dose
according to blood pressure response. The usual maintenance dosage
range is 2.5 mg to 20 mg per
day administered as a single dose or in two equally divided doses. In
some patients treated once
daily, the antihypertensive effect may diminish toward the end of the
dosing interval. In such patients,
consider an increase in dosage or twice daily administration. If blood
pressure is not controlled with
ramipril capsules alone, a diuretic can be added.
2.3 Heart Failure Post-Myocardial Infarction
For the treatment of post-myocardial infarction patients who have
shown signs of congestive heart
failure, the recommended starting dose of ramipril capsules is 2.5 mg
twice daily (5 mg per day). A
patient who becomes hypotensive at this dose may be switched to 1.25
mg twice daily. After one
week at the starting dose, increase dose (if tolerated) toward a
target dose of 5 mg twice daily, with
dosage increases bein